

Glossary

AA, African American
ADLs, activities of daily living
AEs, adverse effects/events
APC, annual percentage change
ASCO, American Society for Clinical Oncology
B(b)/c, because
bev, bevacizumab
BMI, body mass index
BP, blood pressure
carb, carboplatin
CCC, clear-cell carcinoma
Chemo, chemotherapy
CS, corticosteroid(s)
CT, computed tomography
DCR, disease control rate
dMMR, mismatch repair deficient
DOR, duration of response
dostar, dostarlimab
dox, doxorubicin
Dx, diagnose(d)/diagnosis
Dz, disease
EC, endometrial cancer
ECOG, Eastern Cooperative Oncology Group
EEC(s), endometroid endometrial cancer(s)
FDA, Food and Drug Administration
gem, gemcitabine
GI, gastrointestinal
GOG, Gynecologic Oncology Group
HER2, human epidermal growth factor receptor 2
HER2+, HER2-positive
HT, hypothyroid
HTN, hypertension
ICI(s), immune checkpoint inhibitor(s)
IHC, immunohistochemical
ImmunoTx, immunotherapy
irAEs, immune-related adverse events
IV, intravenous
lenva, lenvatinib
levo, levothyroxine
Mb, megabase
mDOR, median duration of response
met(s), metastases
MMRp, mismatch repair protein
mPFS, median progression-free survival
monoTx, monotherapy
mos, months
MSI, microsatellite instability
MSI-H, microsatellite instability high
MSS, microsatellite stable

mut(s), mutation(s)
mut/Mb, mutations per megabase
NCCN, National Comprehensive Cancer Network
NHB, non-Hispanic Black(s)
NHW, non-Hispanic White(s)
NTRK, neurotrophic tyrosine kinase
ORR, objective/overall response rate
OS, overall survival
p53, protein 53
pac, paclitaxel
PC, palliative care
PD-1, programmed death cell protein 1
PD-L1, programmed death cell protein ligand 1
pembro, pembrolizumab
Ph, phase
PFS, progression-free survival
pMMR, mismatch repair proficient
PN, peripheral neuropathy
POLE, polymerase ϵ (epsilon)
PS, performance status
pt(s), patient(s)
Q3W, every 3 weeks (ie, every 21 days)
QOL, quality of life
rEC, recurrent endometrial carcinoma
SDM, shared decision-making
SEC, serous endometrial carcinoma
SEER, Surveillance, Epidemiology and End Results Program
SOC, standard of care
TKI, tyrosine kinase inhibitor
TMB, tumor mutational burden
TMB-H, tumor mutational burden high
TME, tumor microenvironment
TP53, tumor protein 53
TRAEs, treatment-related adverse events
tras, trastuzumab
VEGF, vascular endothelial growth factor
w/, with
wk(s), week(s)
w/o, without
y/o, year old

Drugs: Generic (Trade) Names

atezolizumab (Tecentriq)
bevacizumab (Avastin)
carboplatin (Paraplatin)
cisplatin (Platinol)
doxorubicin (Adriamycin or Rubex)
gemcitabine (Gemzar)
durvalumab (Imfinzi)
lenvatinib (Lenvima)

olaparib (Lynparza)
paclitaxel (Taxol)
pembrolizumab (Keytruda)
rucaparib (Rubraca)
trastuzumab (Herceptin)

Reference List

- Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 2011;29:2259-2265. <https://pubmed.ncbi.nlm.nih.gov/21537039/>
- Arend RC, Jones BA, Martinez A, Goodfellow P. Endometrial cancer: molecular markers and management of advanced stage disease. *Gynecol Oncol*. 2018;150:569-580. <https://pubmed.ncbi.nlm.nih.gov/29843906/>
- Bestvina CM, Fleming GF. Chemotherapy for endometrial cancer in adjuvant and advanced disease settings. *Oncologist*. 2016;21:1250-1259. <https://pubmed.ncbi.nlm.nih.gov/27412393/>
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2018;36:714-1768. <https://ascopubs.org/doi/10.1200/jco.2017.77.6385>
- Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. *Cancer Epidemiol Biomarkers Prev*. 2015;24:1407-1415. <https://pubmed.ncbi.nlm.nih.gov/26290568/>
- Davidson BA, Moss HA, Arquette J, Kama AH. Top ten tips palliative care clinicians should know when caring for patients with endometrial cancer. *J Palliat Med*. 2018;21(6):857–861. <https://pubmed.ncbi.nlm.nih.gov/29649395/>
- Doll KM, Snyder CR, Ford CL. Endometrial cancer disparities: a race-conscious critique of the literature. *Am J Obstet Gynecol*. 2018;218:474-482. <https://pubmed.ncbi.nlm.nih.gov/28964822/>
- Doll KM, Winn AN. Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis. *Am J Obstet Gynecol*. 2019;221:318.e1-318.e9. <https://pubmed.ncbi.nlm.nih.gov/31125544/>
- Erickson BK, Najjar O, Damast S, et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. *Gynecol Oncol*. 2020;159:17-22. <https://pubmed.ncbi.nlm.nih.gov/32709539/>
- Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): updated overall survival analysis. *Clin Cancer Res*. 2020;26:3928-3935. <https://pubmed.ncbi.nlm.nih.gov/32601075/>
- Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. June 16, 2020. Accessed December 15, 2020. <https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors>
- Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA press release. May 23, 2017. Accessed December 15, 2020. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication>

Goebel EA, Vidal A, Matias-Guiu, Gilks CB. The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. *Virchows Arch*. 2018;472:885-896. <https://pubmed.ncbi.nlm.nih.gov/29234950>

Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. *Am Soc Clin Oncol Educ Book*. 2020;40:1-7. <https://pubmed.ncbi.nlm.nih.gov/32213091/>

How J, et al. The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer: an examination of toxicity and treatment efficacy in clinical practice. Presented at: Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women's Cancer; March 19–25, 2021; Abstract 10775.

Longacre TA, Broaddus R, Chuang LT, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. *Arch Pathol Lab Med*. 2017;141(11):1508–1512. <https://pubmed.ncbi.nlm.nih.gov/28301227/>

Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. *Gynecol Oncol*. 2019;155:406-412. <https://pubmed.ncbi.nlm.nih.gov/31677820/>

Lu KH, Broaddus RR. Endometrial Cancer. *N Engl J Med*. 2020;383(21):2053–2064. <https://doi.org/10.1056/NEJMra1514010>

Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2019;20:711-718. <https://pubmed.ncbi.nlm.nih.gov/30922731/>

Makker V, Herraes AC, Aghajanian C, et al. A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*. 2019;37(Suppl15):Abstract TPS5607. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS5607

Makker V, et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer. KEYNOTE-775/Study 309. Presented at: Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women's Cancer; March 19–25, 2021; Abstract 11512.

Makker V, Taylor MH, Aghajanian, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*. 2020;38:2981-2992. <https://pubmed.ncbi.nlm.nih.gov/32167863/>

Marth C, Vulsteke, Rubio Perez MJ, et al. ENGOT-en9/LEAP-001: a phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer. *J Clin Oncol*. 2020;38(Suppl 15):Abstract TPS6106. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS6106

Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer*. 2016;54:139-148. <https://pubmed.ncbi.nlm.nih.gov/26765102/>

Mirza MR, Coleman RL, Hanks LC, et al. ENGOT-EN6/NSGO-RUBY: a phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). *J Clin Oncol*. 2020;38(Suppl 15):Abstract TPS6107. https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS6107

Murali R, Davidson B, Fadare O, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. *Int J Gynecol Pathol*. 2019;38(Suppl 1):S40-S63.

National Cancer Institute. Palliative Care in Cancer. <https://www.cancer.gov/about-cancer/advanced-cancer/care-choices/palliative-care-fact-sheet>. Accessed December 29, 2020.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 1.2021—October 20, 2020. Accessed December 15, 2020. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Management of Immunotherapy-Related Toxicities. Version 1.2020—December 16, 2019. Accessed December 7, 2020. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

Oaknin A, Duska LR, Sullivan RJ, et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer. *Gynecol Oncol*. 2019;154(Suppl 1):33. [https://www.gynecologiconcology-online.net/article/S0090-8258\(19\)30542-6/fulltext](https://www.gynecologiconcology-online.net/article/S0090-8258(19)30542-6/fulltext)

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GARNET. *Ann Oncol*. 2020;31(Suppl 4):LBA36. [https://www.annalsofncology.org/article/S0923-7534\(20\)42348-8/abstract#%20](https://www.annalsofncology.org/article/S0923-7534(20)42348-8/abstract#%20)

Rimel BJ, et al. A randomized, phase II study comparing single-agent Olaparib, single-agent cediranib, and the combination of cediranib/Olaparib in women with recurrent, persistent or metastatic endometrial cancer. Presented at: Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women's Cancer; March 19–25, 2021; Abstract 11636.

Samson K. Endometrial, cervical cancer patients report better quality of life with IMRT. *Oncol Times*. 2016;38(23):34. https://journals.lww.com/oncology-times/Fulltext/2016/12100/Endometrial,_Cervical_Cancer_Patients_Report.11.aspx

Temel JS, Greer JA, El-Jawahri A, et al. Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical. *J Clin Oncol*. 2017;10:35:834-841. <https://pubmed.ncbi.nlm.nih.gov/28029308/>

The Cancer Genome Atlas Research Network (TCGA). Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013;497:67-73. <https://pubmed.ncbi.nlm.nih.gov/23636398/>

Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. *Histopathology*. 2020;76:52-63. <https://pubmed.ncbi.nlm.nih.gov/31846532/5>

Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. *Int J Gynecol Pathol*. 2020;39(1):26-35. <https://pubmed.ncbi.nlm.nih.gov/30741844/>